Platinum sensitivity: BRCA1 mutation
Tan, D. S., C. Rothermundt, et al. (2008). "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations." J Clin Oncol 26(34): 5530-5536.
Nicoletto, M. O., R. Bertorelle, et al. (2009). "Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer." Int J Gynecol Cancer 19(6): 1022-1028.
Platinum sensitivity: p21
Costa, M. J., C. L. Hansen, et al. (1999). "Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21(WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy." Human pathology 30(6): 640-647.
Plisiecka-Halasa, J., G. Karpinska, et al. (2003). "P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens." Ann Oncol 14(7): 1078-1085.
Green, J. A., E. M. Berns, et al. (2006). "Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)." Eur J Cancer 42(15): 2539-2548.
Materna, V., P. Surowiak, et al. (2007). "Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients." Oncol Rep 17(3): 505-516.
Platinum resistance: ERCC1
Lin, K., D. Ye, et al. (2008). "Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer." Int J Gynecol Cancer 18(5): 1007-1012.
Steffensen, K. D., M. Waldstrom, et al. (2009). "The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer." Int J Gynecol Cancer 19(5): 820-825.
Steffensen, K. D., M. Waldstrom, et al. (2008). "Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer." Int J Gynecol Cancer 18(4): 702-710.
Platinum resistance: BRCA1
Quinn, J. E., C. R. James, et al. (2007). "BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy." Clin Cancer Res 13(24): 7413-7420.
Weberpals, J., K. Garbuio, et al. (2009). "The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer." Int J Cancer 124(4): 806-815.
Platinum resistance: Bcl-xL
Williams, J., P. C. Lucas, et al. (2005). "Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease." Gynecol Oncol 96(2): 287-295.
Materna, V., P. Surowiak, et al. (2007). "Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients." Oncol Rep 17(3): 505-516.
Chaudhry, P., R. Srinivasan, et al. (2010). "Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome." Oncol Res 18(11-12): 549-559.
Platinum resistance: Bcl-2
Herod, J. J., A. G. Eliopoulos, et al. (1996). "The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma." Cancer Res 56(9): 2178-2184.
Silvestrini, R., M. G. Daidone, et al. (1998). "The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol." Cancer 82(1): 159-167.
Mano, Y., Y. Kikuchi, et al. (1999). "Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer." Eur J Cancer 35(8): 1214-1219.
Sato, S., J. Kigawa, et al. (1999). "Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma." Cancer 86(7): 1307-1313.
Kupryjanczyk, J., T. Szymanska, et al. (2003). "Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen." Br J Cancer 88(6): 848-854.
Ziolkowska-Seta, I., R. Madry, et al. (2009). "TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens." Gynecol Oncol 112(1): 179-184.
Protopapas, A., E. Diakomanolis, et al. (2004). "The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy." Eur J Gynaecol Oncol 25(2): 225-229.
Chaudhry, P., R. Srinivasan, et al. (2010). "Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome." Oncol Res 18(11-12): 549-559.
Platinum resistance: Metallothionein
Surowiak, P., V. Materna, et al. (2005). "Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients." Virchows Arch 447(3): 626-633.
Surowiak, P., V. Materna, et al. (2007). "Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome." Virchows Arch 450(3): 279-285.
Woolston, C. M., S. Deen, et al. (2010). "Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy." Free Radic Biol Med 49(8): 1263-1272.